Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalClinical and Translational Radiation Oncology
Volume21
DOIs
StatePublished - Mar 2020

Keywords

  • Dose escalation
  • Gynecologic cancer
  • PARP-inhibitors
  • Poly (ADP-ribose) polymerase
  • Radiosensitizer
  • Radiotherapy
  • Talazoparib

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers'. Together they form a unique fingerprint.

Cite this